跳转至内容
Merck
  • Lidocaine attenuates lipopolysaccharide-induced inflammatory responses in microglia.

Lidocaine attenuates lipopolysaccharide-induced inflammatory responses in microglia.

The Journal of surgical research (2014-06-24)
Tong Yuan, Zhiwen Li, Xinbai Li, Gaoqi Yu, Na Wang, Xige Yang
摘要

Lidocaine has been used as a local anesthetic with anti-inflammatory properties, but its effects on neuroinflammation have not been well defined. In the present study, we investigated the prophylactic effects of lidocaine on lipopolysaccharide (LPS)-activated microglia and explored the underlying mechanisms. Microglial cells were incubated with or without 1 μg/mL LPS in the presence or absence of lidocaine, a p38 mitogen-activated protein kinase (p38 MAPK) inhibitor (SB203580), a nuclear factor-kappa B (NF-κB) inhibitor (pyrrolidine dithiocarbamate), or small interfering RNA. The protein and expression levels of inflammatory mediators, such as monocyte chemotactic protein 1, nitric oxide, prostaglandin E2, interleukin 1β, and tumor necrosis factor α were measured using enzyme-linked immunosorbent assays and real-time polymerase chain reaction. The effect of lidocaine on NF-κB and p38 MAPK activation was evaluated using enzyme-linked immunosorbent assays, Western blot analysis, and electrophoretic mobility shift assay. Lidocaine (≥2 μg/mL) significantly inhibited the release and expression of nitric oxide, monocyte chemotactic protein 1, prostaglandin E2, interleukin 1β, and tumor necrosis factor α in LPS-activated microglia. Treatment with lidocaine also significantly inhibited the phosphorylation of p38 MAPK and the nuclear translocation of NF-κB p50/p65, increased the protein levels of inhibitor kappa B-α. Furthermore, our study shows that the LPS-induced release of inflammatory mediators was suppressed by SB203580, pyrrolidine dithiocarbamate, and small interfering RNA. Prophylactic treatment with lidocaine inhibits LPS-induced release of inflammatory mediators from microglia, and these effects may be mediated by blockade of p38 MAPK and NF-κB signaling pathways.

材料
货号
品牌
产品描述

Sigma-Aldrich
荧光素异硫氰酸酯异构体I, suitable for protein labeling, ≥90% (HPLC), powder
Sigma-Aldrich
荧光素 5(6)-异硫氰酸酯, BioReagent, suitable for fluorescence, mixture of 2 components, ≥90% (HPLC)
Sigma-Aldrich
吡咯烷二硫代氨基甲酸铵, ~99%
Sigma-Aldrich
利多卡因 盐酸盐 一水合物, solid
Supelco
利多卡因, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
荧光素 5(6)-异硫氰酸酯, ≥90% (HPLC)
Sigma-Aldrich
荧光素异硫氰酸酯异构体I, ≥97.5% (HPLC)
Sigma-Aldrich
(酪氨酸[SO3H]27)胆囊收缩素片段26-33酰胺, ≥97% (HPLC), powder
Sigma-Aldrich
吡咯烷二硫代氨基甲酸铵, purum p.a., ≥98.0% (NT)
Sigma-Aldrich
荧光素异硫氰酸酯异构体I, ≥97.5% (HPLC)
利多卡因, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
MISSION® esiRNA, targeting human NFKB1
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Nfkb1